Faeth Therapeutics (FTH) vs Yarrow Bioscience (YARW)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Faeth Therapeutics (FTH) has outperformed Yarrow Bioscience (YARW) over the past year, losing 9.6% versus a loss of 26.7%. Over five years, FTH leads with a -95.0% price change compared with -98.6% for YARW. Faeth Therapeutics is the larger company by market cap ($203.7 million vs $196.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FTH | YARW |
|---|---|---|
| Share price | $7.88 | $12.90 |
| Market cap | $203.65M | $196.53M |
| 1-day change | -9.32% | -9.35% |
| YTD return | -26.15% | -55.52% |
| 1-year return | -9.64% | -26.70% |
| 5-year return | -94.96% | -98.61% |
| EPS (TTM) | $-22.50 | — |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $570.00K |
| Revenue growth (YoY) | — | +13.77% |
| Net income (latest FY) | $-21.09M | $-26.48M |
| Operating margin | — | -5219.12% |
| Net margin | — | -4646.14% |
| 52-week high | $42.14 | $46.95 |
| 52-week low | $7.45 | $12.39 |
| Distance from 52-week high | -81.30% | -72.52% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +612.56% | +310.85% |
| Average volume | 500.25K | 153.34K |
| Shares outstanding | 25.84M | 15.23M |
| Employees | 29 | 7 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- FTH has outperformed YARW by 17.1 percentage points over the past year.
About Faeth Therapeutics
FTH stock →Faeth Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees
About Yarrow Bioscience
YARW stock →Yarrow Bioscience, Inc. operates as a clinical-stage biotechnology company that engages in developing transformative therapies for autoimmune thyroid diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
FTH vs YARW FAQ
Which is bigger, Faeth Therapeutics or Yarrow Bioscience?
Faeth Therapeutics (FTH) is larger, with a market capitalization of $203.65M compared with $196.53M for Yarrow Bioscience (YARW).
Which stock has performed better over the past year, FTH or YARW?
FTH returned -9.64% over the past 12 months, compared with -26.70% for YARW (price return, excluding dividends). Past performance does not predict future results.
Are Faeth Therapeutics and Yarrow Bioscience in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.